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impaired endotoxin-induced interleukin-13 secretion, not total produc-
tion, of mononuclear cells from ESRD patients. Lipopolysaccharide
(LPS)-induced interleukin-1 beta (IL-113) and tumor necrosis factor alpha
(TNFa) production and secretion from peripheral blood mononuclear
cells (PBMC) were determined in a longitudinal study with repeated
measurements in PBMC from patients with chronic uremia not on
hemodialysis (N = 8), end-stage renal disease (ESRD) patients (N 8),
and healthy controls (N = 7). ESRD patients were studied while using
low-flux Cuprophan dialyzers and again using high-flux AN 69 dialyzers.
Total (cell-associated plus secreted) LPS-induced IL-i/I production was
enhanced in uremic patients, but similar to controls in ESRD patients on
Cuprophan. In contrast, LPS-induced IL-i/I secretion (secreted amounts
in % of total production) was similar to controls in uremic patients, but
significantly reduced in ESRD patients on Cuprophan (P < 0.01). During
AN 69 hemodialysis, LPS-induced total IL-ill production remained
unchanged but IL-i/I secretion increased significantly (P < 0.05) com-
pared to Cuprophan dialysis. Increased IL-i/I secretion coincided with a
suppression in PGE2 synthesis (P < 0.02). Similarly, blockade of endog-
enous PGE2 by indomethacin increased LPS-induced IL-i/I secretion (P
< 0.01) but did not enhance total IL-i/I production in PBMC from
controls and patients on Cuprophan hemodialysis. Neither total produc-
tion nor secretion of TNFa was different comparing the three study
groups. We conclude that LPS-induced IL-i/I secretion, but not total
production, is impaired in PBMC from ESRD patients on long-term
Cuprophan hemodialysis. This functional change in the PBMC response is
specific for IL-i/I, not due to uremia per se but hemodialysis-dependent
and reversible. Hemodialysis with AN 69 suppresses endogenous POE2
synthesis in PBMC which is associated with increased LPS-induced IL-i/I
secretion in the presence of unchanged total IL-i/I production. We
speculate that PGE2 could inactivate the IL-i/I converting enzyme which
is essential for processing and secretion of mature IL-i/I.
The in vitro production of proinflammatory cytokines such as
IL-I and TNF from PBMC is one way to study differences in the
response of these cells between chronic disease and health [1, 21.
As cytokines play an important role in cell-cell communication,
the total cellular production of IL-i and TNF as well as the
release of these mediators from activated PBMC are important in
the orchestration of the host response system [3, 4]. Although
TNFcs has a signal peptide similar to that of secretory proteins,
TNFa can remain inside the cell [5, 6]. However, in sharp
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contrast, the two interleukin-1 molecules (IL-irs and IL-lp)
clearly lack signal peptides [4]. Despite the missing signal peptide,
as much as 60% of IL-i/I has been found in the supernatant of
lipopolysaccharide- (LPS) stimulated PBMC of healthy volun-
teers in vitro [7, 8].
Cytokine production of PBMC has been used to describe the
effect of orally administered drugs (such as cyclooxygenase inhib-
itors) [9] or dietary supplementation [1, 10]. However, there is a
remarkable intra-individual variability in LPS-induced IL-I/I pro-
duction from PBMC studied on three different days within one
week [1, 9]. Therefore, in order to judge whether a change in
PBMC function due to disease or therapy is meaningful, it is a
prerequisite to describe the intra-individual variability of in vitro
PBMC cytokine production under stable conditions over a defined
period of time.
Patients on chronic hemodialysis therapy have elevated cell-
associated levels of cytokines such as IL-i/I and TNFs in PBMC
determined by immediate lysis after separation or after incubation
[2, 11—13]. Using single point measurements, we have demon-
strated that PBMC from patients on hemodialysis with low-flux
Cuprophan dialyzers produce similar amounts of total (secreted
plus cell-associated) IL-i/I in response to LPS in vitro compared
to PBMC from an age-matched control group [14]. In that study,
LPS-stimulated PBMC secreted significantly less IL-i/I than
PBMC from healthy controls (controls, 56.2 8.3%; Cuprophan
hemodialysis, 31.2 6.3%, P < 0.02). The reduction in IL-1/3
secretion seems to be stimulus dependent since Staphylococcus
epidermidis induced the release of approximately 90% of total
IL-i/I in both groups (controls, 88.1 4.1%; Cuprophan hemo-
dialysis, 89.0 2.7%).
The mechanisms involved in the reduced ability to release
IL-i/I in response to LPS remained unclear. Furthermore, it has
not been determined whether the change in PBMC function is
due to uremia per se or to repeated stimulation by the hemodial-
ysis procedure. Also, the question whether the inflammatory
nature of the dialyzer membrane-induced dysfunction [14, 15] was
reversible remained unanswered.
In order to address these issues, we studied the variability of
TNFa and IL-i/I production and release from LPS stimulated
PBMC from healthy controls, uremic patients with chronic renal
failure as well as from patients with end-stage renal disease
(ESRD) on chronic hemodialysis. We used repeated measure-
ments in PBMC per individual during a period of eight weeks. The
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same ESRD patients were studied in two consecutive eight-week
periods in which they were dialyzed using low-flux Cuprophan
versus high-flux AN 69 dialyzers. We measured PGE2 concentra-
tions in PBMC supernatants and studied the effect of indometha-
cm on LPS-induced IL-1f3 and TNFs production and release from
PBMC.
Methods
Patients and study groups
Two control groups were included in the study. For the
longitudinal study over a time period of 8 weeks, the first group
included seven healthy male volunteers with a mean age of 32.4
years (27 to 42). Blood was drawn from an anticubital vein once a
week in the morning of the same weekday. In a second control
group, 10 healthy volunteers, seven males, three females, donated
blood once for PBMC separation in order to study the effect of
indomethacin on LPS-induced IL-113 and TNFa production and
secretion. None of the volunteers took any medication (cortison,
aspirin or other prostaglandin inhibitors) throughout the study
period.
The first study group included eight uremic patients with
chronic renal failure, two males, six females with a mean age of
53.9 years (31 to 78) who gave informed consent. The diagnosis of
the kidney diseases were polycystic kidney disease in one, diabetic
nephropathy in two, chronic glomerulonephritis in three and
chronic interstitial nephropathy in two. These patients were
studied on each occasion for which they were scheduled for a
routine blood test in the out patient unit. This were three
occasions during the eight-week study period with at least a two
week interval between two samples. In this group, serum concen-
trations were 28.2 4.0 mmol/liter for urea and 699 168
mol/liter for creatinine. The creatinine clearance was 12.7 4.9
ml/min.
The second group included eight male ESRD patients, mean
age 52.9 years (34 to 64), who gave informed consent. These
patients were on hemodialysis therapy with Cuprophan dialyzers
for an average time of 61 months (16 to 132) when entering the
study. The diagnosis leading to end-stage renal failure was
polycystic kidney disease in four, chronic glomerulonephritis in
three and chronic interstitial nephritis in one. Patients with
hepatitis B or C, active hyperparathyroidism or requiring anti-
inflammatory medication were not included.
During the first study period of eight weeks, hemodialysis was
continued using Cuprophan® dialyzers (GF 120 H®, Gambro,
Lund, Sweden) for three hemodialysis sessions per week, with
four to five hours each. Blood was drawn once per week from the
arterio-venous fistula before the start of the dialysis session
following the long inter-dialytic interval, Then all patients
switched to AN 69® dialyzers (Filtral 12®, Hospal, NUrnberg,
Germany). Following a washout period of eight weeks in which no
blood was drawn, the patients entered the second study period of
eight weeks where blood was taken again once a week before
hemodialysis after the long inter-dialytic interval. The effective-
ness of the hemodialysis as indicated by the treatment time, blood
flow in the dialysis machine, post-pre-treatment differences in
serum urea and the weight loss over treatment, was the same in
both study periods (Table 1). In addition, the endotoxin contam-
ination of the dialysate (Limulus test: Coatest® Endotoxin,
KabiVitrum GmbH, Munchen, Germany), which is recognized to
Parameter Cuprophan hemodialysis AN 69 hemodialysis
z Body weight kg 3.00 0.18 3.05 0.24
RR pre-HD mm Hg 149 2.1/88.9 2.7 154.5 3.9/90.6 2.3
RR post-HD mm Hg 140.6 4.8/86.3 3.5 140.6 3.9/85.8 4.4
Urea pre-HD mmoi/iiter 25.36 0.8 26.34 1.1
Urea post-HD mmol/liter 8.94 0.43 8.57 0.54
Urea mmoi/iiter 16.43 0.71 17.77 0.84
Dialysate endotoxin° 19.5 1.5 20.3 0.6
pg/mi
be a potent inducer of PBMC cytokine production [16, 17], was
less than 21 pg/ml and did not differ significantly during the two
study periods (Table 1).
To test the effect of indomethacin on LPS-induced IL-113
production and secretion, PBMC were separated from 10 ESRD
patients on Cuprophan hemodialysis (6 males, 4 females). These
patients are different from those in the study group mentioned
above.
Preparation of human blood mononuclear cells (PBMC)
For the longitudinal study blood was drawn under aseptic
conditions into pyrogen-free tubes containing EDTA (1.5 mglml
of blood) (Sarstedt, Numbrecht, Germany) to which the protein-
ase inhibitor aprotinin was added (0.67 TIU/ml of blood) (Sigma,
St. Louis, MO, USA). The blood was kept on ice and subsequently
processed within 60 minutes. To study the effect of indomethacin,
blood was drawn into pyrogen-free syringes containing 10 IU/ml
heparin.
From each blood sample PBMC were separated by Ficoll-
Hypaque (Seromed, Biochrom KG, Berlin, Germany) centrifuga-
tion. The PBMC were re-suspended to a concentration of 5 X 106
cells/ml in ultrafiltered [18] tissue culture medium (MEM, Whit-
taker M.A. Bioproducts Inc., Walkersville, MD, USA) supple-
mented with 2 mrvi L-glutamine, 10 mM HEPES, 100 U/ml
penicillin, 100 j.g/ml streptomycin (all from Whittaker M.A.) and
2% heat-inactivated human AB serum. One milliliter aliquots
(final concentration 2.5 X 106 PBMC/ml) were incubated in
24-well flat bottom polystyrene plates (NunclonR, A/S Nunc,
Roskilde, Denmark). In the longitudinal study, PBMC were
stimulated with 100 ng/ml LPS from E. coli (phenol-extracted
LPS: 055:B5, Sigma), a dose which induces maximal cytokine
production in normal PBMC [8]. In additional experiments,
PBMC were stimulated with 1 to 100 ng/ml LPS in the presence
and absence of 0.5 j.g/ml indomethacin (Sigma).
During 18 hours of PBMC incubation, temperature was main-
tained at 37°C in an atmosphere containing 5% CO2. After this
period, cell culture supernatants were removed, transferred into
1.5 ml Eppendorf tubes and centrifuged for five minutes at 4°C to
remove remaining cells. Following this centrifugation step, super-
natants containing the extracellular amounts of cytokines were
transferred into new 1.5 ml eppendorf tubes and frozen at —70°C.
The cell pellets (in approximately 20 il of remaining medium) in
the eppendorf tubes were re-suspended in 1 ml of fresh MEM,
added to the adhering PBMC in the corresponding wells of the 24
well plates and kept frozen at —70°C. On the day of the cytokine
Table 1.
Numbers represeni the means SEM of N = 8 averaged values per
patient.
"Dialysate samples were taken from the dialyzer outlet after 3 hours of
hemodialysis
-J
Ca
2
Fig. 1. Total LPS (100 ng/ml)-induced
production (A) and release of IL-1(3 (B) from
PBMC. Each number or letter under the
horizontal axis represents a different individual
(subject). Symbols represent the mean SD of
6 determinations per subject in controls, 3
determinations per subject in uremic patients
(uremia), and 6 to 8 determinations per subject
in ESRD patients on Cuprophan hemodialysis
(CU-HD). Broken horizontal lines indicate the
means per study group: Controls N = 7, uremia
N = 8, and CU-HD N = 8. Total IL-1j3
production is expressed as ng/2.5 X 106 PBMC/
18 hours of incubation; secreted amounts are
depicted as percent of total production. Total
IL-1/3 production was higher in uremia
compared to controls and CU-HD (P < 0.01);
IL-1p secretion was significantly reduced in
CU-HD (P < 0.01) compared to controls and
uremia.
anti-human TNFa and rabbit anti-human IL-1f3) were gifts from
Prof. C.A. Dinarello (New England Medical Center, Boston, MA,
USA). The anti-human IL-113 antiserum detects the mature IL-1f3
peptides (17 kD and 21 kD) as well as 50% of the IL-1f3 precursor
which is not recognized by monoclonal antibodies produced
against the mature form of IL-1f3 [20, 21]. The sensitivity of both
RIAs is approximately 80 pg/mI in PBMC culture supernatants
and cell lysates.
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measurements by radioimmunoassays the 24 well plates were
subjected to three freeze- (—70°C) thaw (37°C) cycles in order to
lyse the PBMC for measurement of cell-associated cytokines.
Cytokine measurements
IL-1p and TNFa were measured by radioimmunoassay (RIA)
in cell culture supernatants and cell lysates as described previously
[7, 19]. The polyclonal antibodies used in each RIA (rabbit
h . ABCDEFGH
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To validate the cytokine assays for repeated measurements, we
determined the intra- and inter-assay variability expressed by the
coefficient of variation (V = sD/mean x 100). Aliquotes of the
same PBMC supernatant and corresponding cell-lysate were
assayed 10 times in one assay, yielding the intra-assay variability of
Vintra = 11.4%; testing the same sample in ten different assays, the
inter-assay variability was Vinter = 11.7%. Hence, to obtain the
total cytokine production level, we added the cell-associated levels
to the extracellular levels. This number was not significantly
different from the actual measured total production in PBMC
when supernatants and cells were lysed together (calculated total
IL-1/3 = 9.9 1.0; measured total IL-1/3 = 10.9 1.3 ngI2.5 X
106 PBMC/18 hr; N = 10).
Prostaglandin B2 (POE2) in the supernatants of LPS-stimulated
PBMC was measured by specific ELISA as previously described
[22]. The detection limit of this assay is 0.25 nglml.
Statistics
Results are given as means standard deviation (sD). Statisti-
cal significance was assessed using one Factor ANOVA analysis.
Post-hoc method of data evaluation was Fisher's PLSD test.
Differences were considered to be significant when P C 0.05.
Results
Decreased release of LPS-induced IL-I /3 from PBMC associated
with hemodialysis
Figure 1 depicts LPS-induced 1L-1f3 production as well as
release from PBMC in the three study groups. The total LPS-
induced IL-1f3 production (Fig. 1A) was similar to that in controls
(4.3 2.7 ng/2.5 x 10' PBMC/18 hrs) and ESRD patients (4.5
1.6) but higher in uremic patients (14.8 5.5, P C 0.01). Secretion
of LPS-induced lL-1/3 (Fig. 1B) was significantly reduced in
PBMC from ESRD patients on chronic hemodialysis using low-
flux Cuprophan dialyzer membranes (32.5 6.3%; P C 0.01)
compared to that of controls (60.8 14.1%) and uremic patients
(61.4 12.6%).
There was intra-individual variability in total lL-1l3 production
in each of the three study groups (Fig. IA). The coefficient of
variation was significantly higher (P C 0.02) in ESRD patients
using Cuprophan dialyzers (62.1 16.7%) compared to uremic
patients (43.4 23.9%) and healthy controls (40.1 13,5%). The
intra-individual variability was significantly reduced in each study
group when the levels of extracellular IL-1/3 were expressed as
percent of total LPS-induced IL-1f3 production. Similar to the
differences in total IL-1f3 production, the intra-individual variabil-
ity for secreted amounts of IL-1/3 was higher in BSRD patients
(36.3 6.34%; P C 0.01) than in normal controls (15.5 5%) and
in uremic patients (15.7 11.8%). In six out of seven control
individuals and seven out of eight uremic patients IL-1/3 release
from PBMC was greater than 50%. However, despite the higher
intra-individual variability, PBMC from patients on hemodialysis
with Cuprophan dialyzers consistently secreted less than 50% of
LPS-induced IL-1/3.
LPS-induced TIs,TFa production and release from PBMC
In contrast to IL-I /3, neither the total production nor the
release of LPS-induced TNFa from PBMC differed significantly
between the three study groups (Fig. 2). Total TNFa production
was 6.8 3.9 ng/2.5 X 10' PBMC/18 hours in controls, 5.2 3.0
ng in uremic patients and 8.8 3.7 ng in ESRD patients. TNFa
release from PBMC was 91.1 4.6% in controls, 88.9 2.5% in
uremic patients and 88.6 4.7% in ESRD patients on Cuprophan
dialyzers.
The intra-individual variability of LPS-induced TNFa produc-
tion (Fig. 2A) was not significantly different from the one de-
scribed for IL-1/3. The coefficient of variation was 53.3 22.1% in
healthy controls, 32.3 18.8% in uremic patients and 58.5
14.4% in ESRD hemodialysis. When the variability was calculated
for secreted TNFa (Fig. 2B), the levels were in the range of 10%,
which falls into the variability of the method used.
LPS-induced PGE2 production from PBMC
As shown in Figure 3, LPS-induced POE2 production was
decreased in PBMC from uremic (20.5 8.3 ng; P C 0.05) and
ESRD patients on hemodialysis with Cuprophan dialyzers (15.2
9.7 ng; P C 0.01) or AN 69 dialyzers (3.9 5.2 ng; P C 0.001)
compared to healthy controls (30.7 9.7). The intra-individual
variability was higher for POE2 than for IL-1/3 and TNFa with
coefficients of variation of 74.4 27.0% in controls, 55.8 43.3%
in uremic patients, 78.8 25.7% in Cuprophan hemodialysis, and
61.4 26.1% in AN 69 hemodialysis.
The suppression of LPS-induced IL-1l3 release is reversible
The ESRD patients on Cuprophan dialyzers were switched to
AN 69 dialyzers and were studied again after a washout period of
eight weeks. Figure 4 depicts the average of eight values for each
patient for total LPS-induced IL-1/3 and TNFa production and
secretion as well as POE2 synthesis. The intra-individual variabil-
ity was not significantly different between the two hemodialysis
periods. The total IL-1/3 and TNFa production decreased in six
out of eight patients but increased in the same two patients,
resulting in a non-significant change when comparing the Cu-
prophan with the AN 69 period. Furthermore, TNFcv release did
not change under the two treatment conditions. After 8 to 16
weeks of hemodialysis using AN 69 dialyzers, IL-1/3 release
increased consistently in each of the eight patients (P C 0.05).
This reversal in IL-1f3 release coincided with a decrease in POE2
production in seven out of eight patients (P C 0.02) when
Cuprophan dialyzers were replaced by AN 69 (Fig. 4).
As there was no time related trend to increased IL-1/3 release
and decreased POE2 production during the AN 69 period, the
washout period of eight weeks was sufficient to reach stable
conditions on AN 69 hemodialysis. Therefore, it was legitimate to
average the eight values per study period.
Inhibition of endogenous PGE2 production by indomethacin
enhances IL -1 /3 release from PBMC
Although the absolute concentrations of POE2 are reduced in
PBMC supernatants from ESRD patients compared to normal
controls, the data shown in Figure 4 suggest that relative changes
in POE2 synthesis influence IL-1f3 secretion. In order to test this
hypothesis, PBMC from healthy volunteers were incubated in the
absence and presence of indomethacin (Table 2). Inhibition of
POE2 did not enhance total IL-1/3 production in response toLPS
(Fig. 5). However, in these same cultures, IL-1/3 secretion in-
creased in the presence of indomethacin in response to 10 ng/ml
Fig. 2. Total TNFa production (A) and TNFa
release (B) from LPS (100 ng/ml)-stimulated
PBMC of healthy controls (N = 7), uremic
patients (N = 8) and ESRDpatients on
Cuprophan hemodialysis (CU-HD, N = 8).
Symbols represent the mean so of 6
determinations per control subject, 3
determinations per uremic patients (uremia),
and 6 to 8 determinations per ESRD patient on
Cuprophan hemodialysis (CU-HD). Broken
horizontal lines indicate the means per study
group. Differences in total TNFa production or
TNFa secretion between the three groups were
not statistically significant.
LPS from 53.1 17.6% to 63.1 15.7% (P < 0.02). In response
to 100 ng/ml LPS, IL-113 secretion increased from 57.7 19.1% to
71.1 16.2% (P <0.01; Fig.5). In response to 100 ng/ml LPS, the
total TNFa production increased from 10.7 3.47 ng to 14.6
5.03 ng in the presence of indomethacin (P < 0.01), but secretion
of TNFa did not change significantly.
When PBMC from ESRD patients on Cuprophan hemodialysis
were studied, total IL-1p production in response to 100 ng/ml LPS
was not enhanced by indomethacin, but IL-1/3 secretion increased
from 44.2 17% to 57.9 18% (P < 0.01) in the presence of
indomethacin (Fig. 5).
Discussion
Suppressed IL-i 13 secretion associated with Cuprophan
hemodialysis
LPS-stimulated PBMC from ESRD patients on chronic hemo-
dialysis with low-flux Cuprophan dialyzers are suppressed in their
ability to secrete IL-1f3, but not TNFc. These data confirm
previous observations [14] and are in agreement with other studies
describing reduced extracellular levels of IL-1f3 in the superna-
tants of LPS-stimulated PBMC from ESRD patients [15, 23, 24].
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Fig. 3. LPS-induced POE2 synthesis by PBMC
from healthy controls, uremic patients and ESRD
patients on hemodialysis with Cuprophan and AN
69 dialyzers. Symbols represent the mean SD
of 6 determinations per control subject, 3
determinations per uremic patient, and 6 to 8
determinations per ESRD patient on
Cuprophan hemodialysis (CU-HD). Broken
horizontal lines indicate the means per study
group. Compared to controls, POE2 synthesis
was reduced in uremia (P C 0.05), Cuprophan
hemodialysis (P C 0.01) and AN 69
hemodialysis (P C 0.001). Switching the same
ESRD patients from Cuprophan to AN 69
decreased in vitro LPS-PGE2 synthesis (P C
0.02).
On the other hand, PBMC from uremic patients not on hemodi-
alysis are not different from those of healthy controls. Thus, the
impaired IL-1/3 release is not caused by uremia per se but is
hemodialysis-dependent. In the present study, suppressed IL-113
secretion was reversed when low-flux Cuprophan dialyzers were
replaced by highly permeable AN 69 dialyzers for at least eight
weeks. When four out of eight ESRD patients were studied again
after one year of AN 69 hemodialysis, their PBMC secreted 60%
of LPS-induced IL-1f3 which is similar to that in healthy or uremic
PBMC (unpublished observation). More IL-1f3 secretion occurred
without a change in total LPS-induced IL-1p production and this
reversal was associated with a decrease in POE2 synthesis. Simi-
larly, inhibition of endogenous POE2 by indomethacin increased
IL-1f3 secretion from LPS-stimulated PBMC of healthy controls
and ESRD patients on Cuprophan. These data suggest that in
ESRD patients as well as in healthy volunteers, down-regulation
of endogenous POE2 increases IL-I 13 secretion rather than total
IL-13 production by PBMC. However, as POE2 synthesis is
reduced in PBMC from ESRD patients compared to normal
controls, the relative changes in POE2 production as opposed to
the absolute amounts seem to influence IL-I f3 secretion.
We studied PBMC in vitro approximately 2.5 days after termi-
nation of the preceding hemodialysis session. Therefore, our data
indicate that blood-dialyzer interactions during hemodialysis may
cause functional changes in PBMC which persist as long as two
days after the end of the hemodialysis procedure. Switching the
dialyzer membrane may persistently modify the PBMC response
to LPS-stimulation. It remains to be established, however,
whether the increased IL-1f3 secretion observed under AN 69
hemodialysis reflects an improved or even a normalized PBMC
function in ESRD patients.
Mechanisms involved in the suppression of IL-1f3 secretion
from PBMC of ESRD patients on long-term Cuprophan hemo-
dialysis are unknown. However, as the dialyzer clearance may play
a role, it is important to state that serum urea levels were not
different comparing the two hemodialysis conditions. Therefore, it
is unlikely that the modified PBMC function during the AN 69
phase was due to better dialyzer clearance of these small molec-
ular substances. We cannot exclude, however, a beneficial effect of
an increased clearance for undefined uremic toxins with a molec-
ular weight of up to 15,000 Daltons which may have an inhibitory
effect on PBMC and which are cleared by the high-flux AN 69 but
not by the low-flux Cuprophan membrane.
The role of POE2
The question whether POE2 synthesis from PBMC in uremic
patients and ESRD patients is altered is controversial. There are
reports of increased [25], unchanged [24] and decreased [26]
POE2 production in PBMC from ESRD patients compared to
cells of healthy controls. In the present study, POE2 production
was reduced in cells from patients during Cuprophan hemodial-
ysis and decreased further during AN 69 usage in the same
patients. This further reduction was associated with an increase in
IL-i/I secretion. However, when individual data were analyzed,
we could not demonstrate a significant inverse correlation be-
tween decreasing POE2 levels and increasing secretion of IL-i/I
under the two dialysis conditions. In a second set of experiments,
blockade of endogenous POE2 production by indomethacin re-
sulted in increased IL-i/I secretion, not total IL-i/I production,
from cells from normal subjects as well as from ESRD patients on
Cuprophan hemodialysis. These data suggest that endogenous
POE2 inhibits LPS-induced IL-i/I secretion but not total synthe-
sis.
Previous reports described that POE2 down-regulates LPS-
induced IL-i/I production [27]. In that study, the secretion of IL-i
into the cell supernatant was measured and, therefore, is consis-
tent with our finding. As in response to 100 nglml LPS total TNFa
production (but not IL-i/I) was significantly enhanced in the
presence of indomethacin, the results presented here are in
agreement with Endres et al who described that POE2 influences
IL-i/I and TNFs production in normal PBMC differently [28].
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Cuprophan AN 69
Fig. 4. The effect of chronic (a minimum of 8
weeks) Cuprophan hemodialysis versus AN 69
hemodialysis on total in vitro IL -1 /3 and TNFa
production and release as well as PGE2 synthesis
by PBMC from ESRD patients. Each symbol
represents the averaged value of 6 to 8
measurements per patient and study period.
The horizontal bars represent the means per
group. The Cuprophan data are the same as in
Figures ito 3. Total IL-113, TNFa, and PGE2
production are expressed as ng/2.5 X 10
PBMC/18 hours of incubation. IL-i/3 and TNFa
release are depicted as percent of total
production. Comparing the two study periods,
IL-113 release increased (P < 0.05) and PGE2
synthesis decreased (P < 0.02) whereas total
IL-1/3, total TNFa and TNFx release did not
differ significantly.
Mechanisms of IL-i /3 secretion
Several mechanisms of IL-1/3 release from LPS-stimulated
PBMC have been introduced. IL-ip is bound in the cytosol,
processed by a specific enzyme and translocated to the plasma
membrane. Release from the cell may involve a process which
probably involves tissue plasminogen activator and serum en-
zymes such as plasmin [29, 30]. A role of protein kinase C (PKC)
has been proposed [31] because PBMC activated by LPS in the
presence of PKC inhibitors do not secrete IL-1f3, whereas total
IL-1/3 production is unaffected. Furthermore, IL-1f3 secretion
seems to be regulated by temperature-sensitive short lived pro-
teins, because preincubation of PBMC for 60 minutes at 42°C
inhibits secretion but only reduces total production of IL-113 [32].
In contrast to an active process of secretion, other studies favor
the concept that IL-i is released from LPS-stimulated PBMC by
a non-specific pathway as a consequence of cellular injury [33]. It
remains to be elucidated whether any of these mechanisms are
different in PBMC from ESRD patients.
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Fig. 5. The effect of indomethacin (0.5 pg/mI)
on total IL-I /3 production and IL-i /3 secretion by
PBMC from healthy controls (Control) and from
ESRD patients on Cuprophan hemodialysis (CU-
HD). PBMC were stimulated with 100 ng/ml
LPS. Total IL-1/3 (•) is depicted on the left
vertical axis as ng/2.5 X 106 PBMC/18 hours of
incubation; secreted IL-1f3 (0) is depicted on
the right vertical axis as percent of total IL-ip
production. The symbols represent individual
data of 10 controls and 10 CU-HD patients.
The control data are the same as those
depicted in Table 2. The horizontal bars
represent the means per group. P < 0.01
compared to PBMC incubations without
indomethacin; NS = not significant. — is no
indomethacin; + is 0.5 pg/mI indomethacin.
Table 2. Effect of indomethacin on LPS-induced IL-1/3 and TNFa
production and secretion
LPS
nglml
Indomethacin
0.5 pg/ml
Total IL-I /3
ng/2.5 X 106
PBMC
Secreted
IL-1/3
% of total
Total TNFa
ng/2.5 X 106
PBMC
Secreted
TNFa
% of total
0 — <0.08 ND 0.26 0.1 ND
+ <0,08 ND 0.32 0.1 ND
1 — 3.9 2.3 51.2 18.1 8.2 2.3 94.9 2.4
+ 3,7 2,4 46.6 21.6 8.8 2.8 96.1 0.4
10 — 11.3 8.7 53.1 17.6 10.1 2.9 94.1 6.2
10.3 6.2 63.1 j5,7a 10.8 3.0 94.4 2.7
100 — 10.4 5.2 57.7 19.1 10.7 3.5 94.2 3.2
+ 11.8 5.6 71.1 162b 14.6 5.0a96.0±1.2
Data are means SD.
P < 0.02, 6P < 0.01 compared to PBMC incubated without indo-
methacin
Processing of IL-i
Our data are also consistent with an impaired processing of the
IL-1/3 precursor molecule into the mature 17 kD IL-113, which is
the major extracellular form of IL-1f3. Impaired processing of
IL-1f3 results in the accumulation of the precursor in the cytosol.
As the precursor is partially recognized by the polyclonal anti-
human IL-1J3 antiserum used in this study, accumulation of the
IL-113 precursor molecule would result in increased cell-associ-
ated levels of IL-1/3. On the other hand, impaired processing will
reduce the appearance of the mature IL-1p molecule in the
extracellular compartment. The enzyme involved in the process-
ing of pro-IL-1f3 is the interleukin-1/3 converting enzyme (ICE)
[34].ThisIL-i convertase is pH sensitive, is optimally active at low
(5.7) external pH and is inactivated at pH 8.0 [32]. One could
propose from the data in this study that ICE is less active in
PBMC from ESRD patients compared to healthy controls. It is
possible that the increase in PGE2 synthesis suppresses either the
synthesis or activation of ICE.
Human ICE is homologous to the Nematode c-elegans 3 (ced-3)
gene which is required for developmental programmed cell death
or apoptosis [35]. Cells undergoing apoptosis express the ced-3
gene. By down-regulating of ICE activity during Cuprophan
hemodialysis, impaired programmed cell death of monocytes!
macrophages could result in longer survival of monocytes in the
circulation. These monocytes are likely to express a cytokine
profile which is different from that of young monocytes. Further
studies are necessary to investigate whether these altered mono-
cytes are present in the circulation of ESRD patients and whether
these cells could account for the immune defect described in these
patients.
Variability in IL-1/3 and TNFcx production
This study describes an intra-individual variation as high as 40
to 60% in LPS-induced production of IL-113 and TNFa in all study
groups. This variability indicates that determination of cytokine
production using single point measurements is not reliable. When
the release of IL-1f3 from LPS stimulated PBMC was expressed as
percent of total production, the coefficients of variation were
reduced to the level of the assay variability. These data suggest
that IL-1/3 release as opposed to total IL-1/3 production is a stable
and reliable parameter to describe PBMC function in longitudinal
studies.
Our observation that the inter-subject variation was highest in
the control group is in agreement with the previously made
distinction between high and low responders for LPS-induced
cytokine production [9]. Studying IL-1f3 release, the inter-individ-
ual variability was high in controls and uremic patients due to one
individual in each group who had consistently reduced amounts of
secreted IL-1f3. These data suggest that the mechanism of IL-1/3
release from PBMC may be, in part, genetically determined.
However, as IL-1/3 secretion was less than 50% in PBMC from all
ESRD patients on Cuprophan treatment, our data suggest an
influence of the hemodialysis procedure on PBMC function.
Neither total TNFa production nor TNFs release was signifi-
cantly different in uremic patients and hemodialysis patients
compared to controls. These data indicate that neither uremiaper
se nor the hemodialysis procedure changes the ability of PBMC to
synthesize and release TNFa in response to LPS. In contrast, total
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LPS-induced IL-1f3 production was higher in PBMC from uremic
patients compared to those from healthy controls and ESRD
patients. Explanations for this observation remain speculative; it is
possible that uremia and/or an active kidney disease causes a
preactivation of PBMC leading to a higher IL-lp production.
However, as different individuals were studied in the uremic
group versus the ESRD group and because of the large intra-
individual variability, the importance of differences in total IL-1f3
production, although statistically significant, should be viewed
with caution.
To our knowledge, our study provides the first evidence that the
impaired ability to secrete IL-I p is predominantly associated with
the hemodialysis procedure itself and not by uremia per Se. If one
assumes that the reduced ability of PBMC to release IL-1/3 plays
a role in the impaired immune response described in hemodialysis
patients [36—38], the results of the present study suggest that
long-term hemodialysis therapy with synthetic high-flux mem-
branes such as AN 69 could improve the ability of PBMC to
secrete IL-1f3 in ESRD patients. Whether this modified PBMC
response observed in vitro is accompanied by an improved im-
mune response remains to be established. However, as the
functional changes of PBMC seem to be induced by the dialysis
procedure, the reduced IL-Ip secretion under the conditions of
long-term Cuprophan hemodialysis may just reflect an adaptation
of the PBMC to protect the patient against the inflammatory
effects of repeated cytokine induction during the extracorporeal
procedure.
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